New product notice

BRILINTA®
ticagrelor tablets

Dear Pharmacist,

AstraZeneca is pleased to announce that BRILINTA (ticagrelor) is now available for Canadian patients.

BRILINTA (ticagrelor), co-administered with acetylsalicylic acid (ASA), is indicated for the secondary prevention of atherothrombotic events in patients with Acute Coronary Syndromes (ACS), including:
• Unstable angina (UA)
• Non-ST elevation myocardial infarction (NSTEMI)
• ST elevation myocardial infarction (STEMI)

Who are to be:
• Managed medically
• Managed with percutaneous coronary intervention (PCI), with or without stent
• Managed with coronary artery bypass graft (CABG)

Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacy of BRILINTA compared to clopidogrel, BRILINTA is recommended to be co-administered with a low maintenance dose ASA (75-150 mg daily).

BRILINTA is available as 90 mg tablets

Strength 90 mg blister compliance pack
DIN 236854
UPC 6 20641 014473
Product number 1447
Unit of sale 1 x 60 tab pack (4 x 15 tab blisters)
Netlist price $88.80
Taxable No

The recommended daily dosage of BRILINTA is as follows:


*Unless specifically contraindicated


For further product or medical information enquiries, you may contact the Medical Information Department by:
Phone 1-800-668-6000
Email medinfo.canada@astrazeneca.com
Website www.astrazeneca.ca

BRILINTA is contraindicated in patients who: are hypersensitive to this medication or to any ingredient in the formulation, have active pathological bleeding such as peptic ulcer or intracranial hemorrhage, have a history of intracranial hemorrhage, have moderate to severe hepatic impairment and/or are also taking strong CYP3A4 inhibitors.

BRILINTA should be used with caution in patients with a propensity to bleed (e.g., due to recent trauma, recent surgery, active or recent gastrointestinal bleeding or moderate hepatic impairment) and in patients requiring oral anticoagulants (e.g., warfarin) and/or fi brinolytics agents (within 24 hours of BRILINTA dosing). Caution should also be used in patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g., non-steroidal anti-infl ammatory drugs [NSAIDs]). Co-administration of BRILINTA and a high maintenance dose ASA (>150 mg daily) is not recommended.

In the PLATO study, bleeding events associated with BRILINTA were 11.6% total major and 16.1% combined total major + minor. The most common adverse events associated with BRILINTA were dyspnea (12.0%), headache (6.5%) and nosebleed (6.0%).

See the Product Monograph for full contraindications, warnings, precautions, dosing and administration.

Yours truly,
Tyler Darroch
Senior Marketing Manager - BRILINTA (ticagrelor)

Reference: 1. BRILINTA® Product Monograph. AstraZeneca Canada Inc. May 26, 2011.


BRILINTA® and the AstraZeneca logo are registered trademarks
of the AstraZeneca group of companies. © AstraZeneca 2011

AstraZeneca Canada Inc.
1004 Middlegate Road, Mississauga, Ontario, Canada L4Y 1M4
www.astrazeneca.ca TEL (905) 277-7111 FAX (905) 270-3248